Studies related to C-Reactive Protein and Ashwagandha

Adjunctive Use Of A Standardized Extract Of Withania Somnifera (Ashwagandha) To Treat Symptom Exacerbation In Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

Effect Decrease
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 68
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Body Types Obese, Overweight, Average, Underweight
Notes for this study:
In a randomized, double-blind, placebo-controlled trial 64 schizophrenia patients were assigned to take placebo or 500 mg of an ashwagandha extract for the first week and 1000 mg for the remaining 11 weeks of the trial.

The primary outcome was the severity of schizophrenia systems as assessed by PANSS. Participants taking ashwagandha saw a modest, statistically significant reduction in their total symptoms compared with placebo. They also saw a notable reduction in perceived stress. Markers of inflammation, hsCRP, and S100B declined in the ashwagandha group and increased in the placebo group, but the difference wasn't statistically significant. There was no change in IL-6. There was no significant difference in blood pressure or body weight between the groups at the end of the trial.

No statistically significant differences in adverse events were found between the groups.
Funding issues for this study:
"This clinical trial was funded by the Stanley Medical Research Institute, Maryland, under grant award 12T-001. Natreon, Inc., New Jersey, provided the standardized extract of Withania somnifera and placebo."

"Dr Chengappa states that the University of Pittsburgh is pursuing intellectual property protection for the technology discussed in this article. Drs Brar and Gannon and Ms Schlicht have no conflicts of interest to disclose with regard to this study."

"Neither the Stanley Medical Research Institute nor Natreon, Inc. had any role in conducting the clinical trial, data gathering, or analyses or reporting of the study results."

A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
Effect Decrease
Values mg/dl. Placebo: before 6.4 (3.7), after 6.0 (3.7). 125 mg before 3.8 (1.2), after 2.6 (1.1). 250 mg before 4.1 (1.0), after 2.6 (1.0). 500 mg before 5.4 (1.4), after 3.5 (2.6)
Trial Design randomized
Trial Length 16months
Number of Subjects 130
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Funding issues for this study:
"We would like to thank Natreon Inc. (New Brunswick, New Jersey) for financial support of this study. " "Dr. Auddy is an employee of Natreon Inc., which is the patent holder of Withania somnifera extract sold under the trade names Essentra® and Sensoril®. Dr. Abedon is an employee of NutraGenesis LLC, which sells Withania somnifera extract exclusively under the trade names Essentra® and Sensoril®. Dr. Ghosal was an unpaid adviser to Natreon Inc. at the time the study was conducted."